Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Phillip J MeaseAlexis OgdieJohn TesserNatalie J ShiffRuizhi Sophia ZhaoSoumya D ChakravartyMichael KellemanRhiannon DodgeRobert R McLeanAaron BroadwellArthur KavanaughJoseph F MerolaPublished in: ACR open rheumatology (2024)
Pain and physical function are important contributors to health-related quality of life. In this real-world population of patients with treatment-resistant PsA and 6 months of persistent guselkumab treatment, clinically meaningful improvements in pain and physical function were achieved by approximately 40% and 30% of patients, respectively.
Keyphrases
- patient reported outcomes
- chronic pain
- end stage renal disease
- prostate cancer
- pain management
- neuropathic pain
- newly diagnosed
- chronic kidney disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- rheumatoid arthritis
- electronic health record
- big data
- spinal cord injury
- ankylosing spondylitis
- deep learning
- artificial intelligence